We found that the 5-day-on/2-day-off palbociclib schedule caused a significant reduction in skeletal tumour burden at every timepoint measured, demonstrating that CDK4/6 inhibition can impede TNBC growth in bone (Figure 3C). Here, CDK4 is linked to neoplasm.